Market Research Logo

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2015

Introduction
Global Markets Direct Report Coverage
Acute Respiratory Distress Syndrome Overview
Therapeutics Development
Pipeline Products for Acute Respiratory Distress Syndrome - Overview
Pipeline Products for Acute Respiratory Distress Syndrome - Comparative Analysis
Acute Respiratory Distress Syndrome - Therapeutics under Development by Companies
Acute Respiratory Distress Syndrome - Therapeutics under Investigation by Universities/Institutes
Acute Respiratory Distress Syndrome - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Acute Respiratory Distress Syndrome - Products under Development by Companies
Acute Respiratory Distress Syndrome - Products under Investigation by Universities/Institutes
Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development
Altor BioScience Corporation
Athersys, Inc.
BioMarck Pharmaceuticals, Ltd.
Faron Pharmaceuticals Oy
FirstString Research, Inc.
GlaxoSmithKline Plc
Histocell S.L.
Myelo Therapeutics GmbH
Phylogica Limited
Serendex Pharmaceuticals A/S
Silence Therapeutics Plc
Therabron Therapeutics, Inc.
Acute Respiratory Distress Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ALT-836 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIO-10901 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CG-367 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyndacel-M - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-2586881 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-2862277 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon beta-1a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
molgramostim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MultiStem - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Myelo-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PYC-35 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PYC-36 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PYC-38 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PYC-98 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Proteins for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-1229 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAN-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Inflammatory Lung Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stromal Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acute Respiratory Distress Syndrome - Recent Pipeline Updates
Acute Respiratory Distress Syndrome - Dormant Projects
Acute Respiratory Distress Syndrome - Discontinued Products
Acute Respiratory Distress Syndrome - Product Development Milestones
Featured News & Press Releases
May 27, 2015: Phase I clinical trial of inhaled molgramostim has commenced
May 20, 2015: Novozymes Biopharma enables stable formulation of Serendex Pharmaceutical’s inhalable biological drug for treatment of severe pulmonary diseases
Jan 22, 2015: Athersys and Cell Therapy Catapult Announce Grant to Support Clinical Development of Stem Cell Therapy for Severe Acute Respiratory Condition
Dec 02, 2014: Traumakine development in Japan
Jan 02, 2014: Promising new treatment for life threatening acute respiratory distress syndrome
Dec 20, 2013: Faron receives scientific advice from the EMA on the FP-1201-lyo clinical development
Nov 29, 2012: Faron Pharma Receives €6m Grant From European Commission For Traumakine Program
May 21, 2012: Faron Pharma Announces Presentation Of New data From ALI/ARDS FPCLI001 Study At 2012 American Thoracic Society Meeting
Oct 07, 2011: Faron Completes Phase I/II Clinical Trial With FP-1201 In Acute Lung Injuries
May 23, 2011: Altor BioScience Receives D3m SBIR Phase II Competing Renewal Grant From NHLBI
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2015
Number of Products under Development for Acute Respiratory Distress Syndrome - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Acute Respiratory Distress Syndrome - Pipeline by Altor BioScience Corporation, H2 2015
Acute Respiratory Distress Syndrome - Pipeline by Athersys, Inc., H2 2015
Acute Respiratory Distress Syndrome - Pipeline by BioMarck Pharmaceuticals, Ltd., H2 2015
Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, H2 2015
Acute Respiratory Distress Syndrome - Pipeline by FirstString Research, Inc., H2 2015
Acute Respiratory Distress Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2015
Acute Respiratory Distress Syndrome - Pipeline by Histocell S.L., H2 2015
Acute Respiratory Distress Syndrome - Pipeline by Myelo Therapeutics GmbH, H2 2015
Acute Respiratory Distress Syndrome - Pipeline by Phylogica Limited, H2 2015
Acute Respiratory Distress Syndrome - Pipeline by Serendex Pharmaceuticals A/S, H2 2015
Acute Respiratory Distress Syndrome - Pipeline by Silence Therapeutics Plc, H2 2015
Acute Respiratory Distress Syndrome - Pipeline by Therabron Therapeutics, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Acute Respiratory Distress Syndrome Therapeutics - Recent Pipeline Updates, H2 2015
Acute Respiratory Distress Syndrome - Dormant Projects, H2 2015
Acute Respiratory Distress Syndrome - Dormant Projects (Contd...1), H2 2015
Acute Respiratory Distress Syndrome - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2015
Number of Products under Development for Acute Respiratory Distress Syndrome - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Acute Respiratory Distress Syndrome - Pipeline Review, H2 2015’, provides an overview of the Acute Respiratory Distress Syndrome’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Respiratory Distress Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Respiratory Distress Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Acute Respiratory Distress Syndrome and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Acute Respiratory Distress Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Acute Respiratory Distress Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acute Respiratory Distress Syndrome
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;